NASDAQ · IXHL
Incannex Healthcare Limited
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
Loading market information…
ASX · BNO.AX · AUD
Stock price, earnings
Quote as of Aug 24, 2023, 04:34 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Bionomics Limited’s quoted price sits in the lower half of its reported 52-week range, 87.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bionomics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1996 and headquartered in Eastwood, Australia, Bionomics Limited operates as a clinical-stage biopharmaceutical firm. The company's mission is to identify and advance innovative drug treatments, primarily focusing on central nervous system (CNS) conditions and various forms of cancer. Its key experimental therapeutic, BNC210, is a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor, currently undergoing Phase 2 trials for social anxiety disorder and more advanced Phase 2b trials for post-traumatic stress disorder (PTSD). Bionomics' pipeline also includes BNC101, a monoclonal antibody designed to specifically target cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Furthermore, BNC105 is advancing through Phase 2 trials for refractory colorectal cancer and Phase 1 trials for individuals with relapsed or refractory chronic lymphocytic leukemia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.58-$0.13 (-4.8%)
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
A$0.42+A$0.01 (+2.44%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.18% below the high.
A$0.04A$0.00 (0.0%)
AusCann Group Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 4.76% below the high.
A$0.01+A$0.00 (+22.22%)
1st Group Limited’s quoted price sits in the upper half of its reported 52-week range, 26.67% below the high.
A$6.60A$0.00 (0.0%)
Medlab Clinical Limited: Healthcare · Biotechnology.
A$0.04A$0.00 (0.0%)
Asian American Medical Group Limited: Healthcare · Medical - Care Facilities.
A$0.04-A$0.00 (-6.98%)
Rhinomed Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
